BGNE BeOne Medicines Ltd.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $380M on the open market; over its last four quarters it reported revenue of $6.13B and net income of $656M.
BGNE revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.71B, net income $237M, EPS 0.16
- Quarter ended Mar 31, 2026: revenue $1.51B, net income $227M, EPS 0.15
- Quarter ended Dec 31, 2025: revenue $1.50B, net income $66.5M, EPS 0.05
- Quarter ended Sep 30, 2025: revenue $1.41B, net income $125M, EPS 0.08
Recent BGNE insider trades
- Oct 13, 2026: Wang Xiaodong sold 31,027 shares ($10.9M)
- Sep 30, 2026: Lee Chan Henry sold 1,115 shares ($418K)
- Sep 28, 2026: Wang Xiaodong sold 31,028 shares ($11.3M)
- Sep 8, 2026: Wang Xiaodong sold 38,287 shares ($13.4M)
5%+ owners
- Julian C. Baker: 7.8% (Schedule 13D/A, filed Sep 16, 2026)
Are insiders buying or selling BGNE?
Over the last 12 months insiders bought $0 and sold $380M of BeOne Medicines Ltd. stock on the open market (SEC Form 4).
What was BGNE's revenue last quarter?
BeOne Medicines Ltd. reported revenue of $1.71B for the quarter ended June 30, 2026, with net income of $237M.